The biotech sector faces an uncertain market outlook dominated by variables like tax policies, tariffs, and interest rates as key determinants of future growth. EY analysts underscore constrained investment environments and advise focused resource allocation to high-potential assets. Notably, several biotech financings and IPOs continue, including Caris Life Sciences’ $494M IPO and various funding rounds in Asia-Pacific. Sector participants must navigate complex geopolitical and economic landscapes, while leveraging innovation—especially in AI—to maintain productivity and capitalize on eventual market rebounds.